4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow

Zacks2024-12-24

The Zacks Medical space comprises a diversified set of players, ranging from health insurers, hospitals and nursing homes to medical device companies. With a few days left for 2024 to conclude, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493038794?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DzBDGkDks11YfbV06v4Jcg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b693231ec652d955b89ef0825efe25b1","is_english":true,"pubTime":"2024-12-24 22:09","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493038794","market":"us","top_or_hot":-1,"title":"4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow","media":"Zacks","content":"<div>\n<p>The Zacks Medical space comprises a diversified set of players, ranging from health insurers, hospitals and nursing homes to medical device companies. With a few days left for 2024 to conclude, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/4-healthcare-stocks-rising-more-140900418.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 22:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/4-healthcare-stocks-rising-more-140900418.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Zacks Medical space comprises a diversified set of players, ranging from health insurers, hospitals and nursing homes to medical device companies. With a few days left for 2024 to conclude, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/4-healthcare-stocks-rising-more-140900418.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/4-healthcare-stocks-rising-more-140900418.html","article_id":"2493038794","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DzBDGkDks11YfbV06v4Jcg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b693231ec652d955b89ef0825efe25b1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493038794","pubTimestamp":1735049340,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The Zacks Medical space comprises a diversified set of players, ranging from health insurers, hospitals and nursing homes to medical device companies. With a few days left for 2024 to conclude, factors such as a strong membership base, rising patient volumes, resumption of elective procedures, continued incidence of mental health issues and technology advancements played a pivotal role in shaping the performance of the sector so far this year.However, the persistence of inflationary challenges continued to inflict adversities on the sector’s performance in the form of escalating healthcare costs.However, rising healthcare costs, compounded by inflation, remain a concern. Inflation has also disrupted medical supply chains and increased labor costs, leaving healthcare providers grappling with operational challenges.Nevertheless, the medical sector's participants remain active in mergers and acquisitions to enhance capabilities, diversify their portfolios, expand customer bases and streng","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","BK4137":"综合支持服务","LU0882574055.USD":"富达全球健康医疗A ACC","BSX":"波士顿科学","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","HCSG":"医疗保健服务","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","DOCS":"Doximity, Inc.","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","GMED":"Globus Medical Inc","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4167":"医疗保健技术","LU0122379950.USD":"贝莱德世界健康科学A2","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LMAT":"勒梅特微管医疗","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","BK4551":"寇图资本持仓","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"4只医疗保健股2024年涨幅超过50%且有增长空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1,"DOCS":1,"GMED":1,"HCSG":1,"LMAT":0.9},"content_text":"The Zacks Medical space comprises a diversified set of players, ranging from health insurers, hospitals and nursing homes to medical device companies. With a few days left for 2024 to conclude, factors such as a strong membership base, rising patient volumes, resumption of elective procedures, continued incidence of mental health issues and technology advancements played a pivotal role in shaping the performance of the sector so far this year. \nHowever, the persistence of inflationary challenges continued to inflict adversities on the sector’s performance in the form of escalating healthcare costs.\nUnderlying Trends of the Medical Sector\nHealth insurers are increasingly designing affordable health plans and expanding their reach into underserved U.S. communities facing limited access to care. These plans are frequently enhanced with attractive features, driving contract wins and renewals with federal and state authorities. Such agreements support membership growth and increase premiums, the primary revenue source for health insurers. Additionally, the aging U.S. population is expected to sustain robust demand for Medicare plans in 2025.\nHealthcare facility operators benefit from higher patient volumes on the resumption of deferred elective procedures. This trend is expected to bring more patients to surgery centers, lead to a rise in elective surgeries and therefore, improve inpatient occupancy levels. \nThe growing need for specialized rehabilitative care to help patients recover from chronic illnesses and injuries has driven revenue growth for companies offering inpatient rehabilitation services. Similarly, operators of behavioral health and psychiatric hospitals have benefited from the rising prevalence of mental health issues among Americans.\nHowever, rising healthcare costs, compounded by inflation, remain a concern. Inflation has also disrupted medical supply chains and increased labor costs, leaving healthcare providers grappling with operational challenges. \nThe medical device industry has encountered considerable challenges this year, particularly in the U.S. and European markets. These difficulties have been due to regulatory hurdles, supply-chain disruptions and geopolitical tensions, which have significantly altered the industry landscape. Originally sparked by the COVID pandemic, global supply-chain disruptions continued throughout 2024. Escalating raw material costs and semiconductor shortages have severely impacted device production. Additionally, inflation in the United States and Europe has exacerbated the situation, driving up operational expenses and squeezing profit margins.\nThe Zacks Medical sector has declined 6% year to date against the S&P 500’s 25.3% increase. \nImage Source: Zacks Investment Research\nNevertheless, the medical sector's participants remain active in mergers and acquisitions to enhance capabilities, diversify their portfolios, expand customer bases and strengthen their global presence. Strong financial positions enable them to pursue these growth strategies.\nAmid the ongoing wave of digitization and the convenience it brings, healthcare companies continue to invest heavily in telehealth services. Despite the associated expenses linked with such technology investments, these initiatives are expected to generate consistent revenue streams and be beneficial for healthcare providers in the long term.\nFour Healthcare Stocks to Watch Before 2024 Ends\nGiven the backdrop, we have selected four medical stocks, Doximity, Inc. DOCS, Boston Scientific Corporation BSX, LeMaitre Vascular, Inc. LMAT and Globus Medical, Inc. GMED, that offer a mix of stability and growth potential that investors can leverage heading into 2025. While no investment is without risks, these companies are well-positioned to deliver strong returns. \nEach of these companies sports either a Zacks Rank #1 (Strong Buy) or carries a Zacks Rank #2 (Buy), witnessed positive earnings estimate revisions for 2025 and gained more than 50% on a year-to-date basis. You can see the complete list of today’s Zacks #1 Rank stocks here.\nDoximity: Headquartered in California, the Zacks Rank #1 company capitalizes on growth opportunities through strategic acquisitions, robust adoption of AI-powered productivity solutions and increasing monetization of telehealth and patient-facing tools, which enhance its service offerings and customer engagement. Additionally, its leadership in digital networking among healthcare professionals positions it as the preferred partner for organizations aiming to connect with this audience, driving sustained demand for its services and reinforcing its long-term growth trajectory. \nThe Zacks Consensus Estimate for DOCS’ fiscal 2025 earnings is pegged at $1.14 per share, indicating 20% year-over-year growth. It has witnessed eight upward estimate revisions in the past 60 days against none in the opposite direction. Doximity’s earnings surpassed estimates in each of the last four quarters, the average  surprise being 22.12%. Its shares have surged 107.5% year to date.\nAverage Broker Recommendation: 2.40\nDoximity, Inc. Price and EPS Surprise\n\n  \nDoximity, Inc. price-eps-surprise | Doximity, Inc. Quote\n\nBoston Scientific: The Massachusetts-based company benefits from robust international expansion. BSX’s diversified portfolio and innovative technologies, such as the WATCHMAN device and FARAPULSE PFA system, are gaining global traction, supported by strategic approvals in Japan and China. Strong MedSurg market share gains in Endoscopy and Urology, coupled with value-adding acquisitions like Silk Road Medical and Axonics, further bolster its position. Additionally, the growing Electrophysiology market and new product launches provide significant growth potential for the Zacks Rank #2 company. \nThe Zacks Consensus Estimate for BSX’s 2024 earnings is pegged at $2.46 per share, which indicates a year-over-year improvement of 20%. The consensus mark for 2025 earnings indicates further year-over-year growth of 12.7%. It has witnessed two upward estimate revisions for 2025 earnings in the past 30 days against none in the opposite direction. Boston Scientific’s earnings surpassed estimates in each of the last four quarters, the average surprise being 8.29%. Its shares have gained 55.4% year to date. \nAverage Broker Recommendation: 1.26\nBoston Scientific Corporation Price and EPS Surprise\n\n  \nBoston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote\n\nLeMaitre Vascular: Based in Massachusetts, LeMaitre Vascular is benefiting from expanding demand for vascular medical devices driven by an aging global population and the rising prevalence of chronic vascular diseases. This Zacks Rank #2 company leverages its global reach and diversified product portfolio to meet increasing needs in minimally invasive treatments. Additionally, advancements in healthcare infrastructure, growing adoption of technologically advanced devices and favorable reimbursement policies enhance market opportunities. Strategic acquisitions and consistent R&D investments further strengthen its competitive positioning. The Zacks Consensus Estimate for LMAT’s 2024 earnings is pegged at $1.94 per share, indicating 43.7% year-over-year growth. The consensus mark for 2025 earnings indicates further year-over-year growth of 11.3%. It has witnessed five upward estimate revisions for 2025 earnings in the past 30 days against none in the opposite direction. LeMaitre Vascular’s earnings surpassed estimates in each of the last four quarters, the average surprise being 10.10%. Its shares have gained 61% year to date. \nAverage Broker Recommendation: 1.67\nLeMaitre Vascular, Inc. Price and EPS Surprise\n\n  \nLeMaitre Vascular, Inc. price-eps-surprise | LeMaitre Vascular, Inc. Quote\n\nGlobus Medical: The Pennsylvania-based company is capturing market share in the musculoskeletal solutions space, supported by its innovative portfolio of implantable devices, biologics and robotic technologies. Its merger with NuVasive has created a global leader with expanded international reach, enhanced synergies and a strengthened product offering for surgeons and patients. Industry trends, such as an aging population and increasing prevalence of musculoskeletal disorders, are further providing Globus Medical with an opportunity to capitalize on. With a robust pipeline, high R&D investment and consistent product launches, coupled with solid financial health and strong execution, the Zacks Rank #2 company is poised for continued success.\nThe Zacks Consensus Estimate for GMED’s 2024 earnings is pegged at $2.97 per share, which indicates a year-over-year improvement of 28%. The consensus mark for 2025 earnings indicates further year-over-year growth of 16.3%. It has witnessed two upward estimate revisions for 2025 earnings in the past 30 days against one in the opposite direction. Globus Medical’s earnings surpassed estimates in each of the last four quarters, the average surprise being 17.65%. Its shares have gained 55.9% year to date. \nAverage Broker Recommendation: 1.80\nGlobus Medical, Inc. Price and EPS Surprise\n\n  \nGlobus Medical, Inc. price-eps-surprise | Globus Medical, Inc. Quote\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nLeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nDoximity, Inc. (DOCS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493038794"}